AstraZeneca

DelveInsight's report on the Obsessive Compulsive Disorder (OCD) market forecasts a significant CAGR growth from 2020-2034, driven by increasing prevalence and awareness, and the launch of multiple-stage pipeline products. The market was valued at approximately USD 1000 million in 2023, with 12,082,000 prevalent cases of OCD across 7MM in 2022, expected to rise by 2034. Key companies include Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, and others, with therapies such as Troriluzole, Fluvoxamine maleate, and BHV-4157. The report provides insights into epidemiology, market trends, and treatment scenarios in the US, EU4, and Japan.

DelveInsight's report on Urothelial Carcinoma Market (2020-2034) highlights market trends, epidemiology, and key companies/therapies. The market size was ~USD 900 million in 2023, expected to grow significantly. Key companies include Merck, Bristol Myers Squibb, and others. Therapies like KEYTRUDA and OPDIVO are prominent. The U.S. leads in market share and incident cases. Pipeline candidates and increased awareness drive market growth.

Treg sector sees significant investments and collaborations, positioning Treg therapies as a breakthrough in autoimmune and inflammatory disease treatments. The 7th Treg-Directed Therapies Summit (March 25-27, 2025, Revere Hotel, Boston) offers insights into Treg biology and clinical advancements.

Ozempic, a diabetes and weight loss drug, has become one of the most popular medications in the U.S., with over 1 in 8 Americans using it. Despite side effects like nausea and weight loss plateaus, its sales continue to rise, driven by pandemic and celebrity influences. Newer GLP-1 drugs like Tirzepatide and Semaglutide promise more weight loss, while drugs in clinical trials such as Orforglipron and CagriSema aim to address current limitations. However, high costs and limited insurance coverage remain significant barriers to access.

Precision Medicine Market valued at USD 78.6 Billion in 2023, projected to reach USD 156.1 Billion by 2030, driven by technological advancements, rising chronic diseases, and collaborations. North America leads, followed by Europe and Asia-Pacific. Key players include AstraZeneca, Illumina, Johnson & Johnson, and Novartis.

AstraZeneca’s Imfinzi (durvalumab) granted Priority Review by FDA for muscle-invasive bladder cancer treatment, based on NIAGARA Phase III trial data showing reduced risk of disease progression, recurrence, and death. Imfinzi demonstrated a 32% reduction in risk of disease progression and a 25% reduction in risk of death compared to standard neoadjuvant chemotherapy.

Two studies show nirsevimab effectively protects infants from RSV, with no viral replacement. In a New York City study, 45% of infants received nirsevimab within their first 7 days of life.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca, a global biopharmaceutical company, focuses on oncology, rare diseases, and bio-pharmaceuticals, aiming to redefine cancer care and eliminate it as a cause of death.

FDA approves AstraZeneca’s Imfinzi for LS-SCLC treatment, supported by ADRIATIC trial results showing improved median overall survival of 22.5 months.

FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, showing significant survival and progression benefits in ADRIATIC trial.